Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 11:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adverse Drug Events Clear all
Recruiting Phase 3 Interventional

Melatonin for Prevention of Kidney Injury

NCT05084196
View directory record Official record
Conditions
Acute Kidney Injury, Adverse Drug Event
Interventions
Melatonin, Placebo Capsule
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 22, 2026, 11:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

DOAC ADRs Retrospective Study on Genetic Variations

NCT04580589
View directory record Official record
Conditions
Drug-Related Side Effects and Adverse Reactions, Treatment Failure
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Adverse Drug Events With PatientSite

NCT00140504
View directory record Official record
Conditions
Adverse Drug Event
Interventions
Medcheck message
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Not applicable Interventional

Drug-Related Problems and Healthcare Utilization Post-Hospital Discharge

NCT01806038
View directory record Official record
Conditions
Drug Related Problems Post Hospital Discharge, Healthcare Utilization, Discharge Medication Counseling
Interventions
RPh Counseling + Outpatient Med Dispensing at Discharge, Discharge Med Dispensing Plus Counseling - Current Practice
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCT04255433
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
13,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Concord, California • Covina, California + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 22, 2026, 11:33 PM EDT
Terminated Phase 4 Interventional Results available

Post-operative Pain Control After Pediatric Adenotonsillectomy

NCT02296840
View directory record Official record
Conditions
Recurrent Tonsillitis, Obstructive Sleep Apnea, Sleep Disordered Breathing, Adverse Reaction to Drug
Interventions
Ibuprofen, Hydrocodone-Acetaminophen
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Sep 22, 2026, 11:33 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

DOAC ADRs Retrospective Study

NCT04247919
View directory record Official record
Conditions
Drug-Related Side Effects and Adverse Reactions
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 22, 2026, 11:33 PM EDT
Completed No phase listed Observational Results available

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

NCT04682587
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, Avelumab, Pembrolizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Phase 4 Interventional

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

NCT04340388
View directory record Official record
Conditions
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions
Dolutegravir 50 MG, Antiretroviral/Anti HIV
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interactive Digital Health Tools to Improve Patient Safety in Acute Care

NCT03116074
View directory record Official record
Conditions
Transitions of Care, Patient Portals, General Medicine, Discharge Checklist, Patient-provider Communication, Adverse Event, Readmission
Interventions
Interactive Digital Health Tools
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Not applicable Interventional Results available

Pharmacogenetic Testing Among Home Health Patients

NCT02378220
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Pharmacogenetic testing
Genetic
Lead sponsor
Genelex Corporation
Industry
Eligibility
50 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Searcy, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

NCT06673238
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-722, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Cypress, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Not applicable Interventional Results available

Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults

NCT04284553
View directory record Official record
Conditions
Aging, Benzodiazepine Sedative Adverse Reaction, Anticholinergic Adverse Reaction, Adverse Drug Event
Interventions
Order Entry, Open Encounter, Follow-up booster Alert, Cold State outreach, Simplified, Sign-off alert, Pre-commitment, Different Risks, Standard Epic Basic Alert, Enhanced Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Braintree, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 22, 2026, 11:33 PM EDT
Terminated Phase 4 Interventional

Pain Control After Minimally Invasive Coronary Artery Bypass Grafting

NCT01770236
View directory record Official record
Conditions
Postoperative Pain, Medication Side Effects, Narcotic Requirement
Interventions
IV acetaminophen
Drug
Lead sponsor
Gundersen Lutheran Medical Foundation
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Sep 22, 2026, 11:33 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Partnering With Patients for Improving Medication Safety During Transitions of Care: Implications for Work System Design

NCT03544034
View directory record Official record
Conditions
Patient Safety, Adverse Drug Event
Interventions
HomeTeam Toolkit
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

NCT03576469
View directory record Official record
Conditions
CVI - Common Variable Immunodeficiency
Interventions
C1-esterase inhibitor [recombinant] (C1-INH-R)
Biological
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Not applicable Interventional Results available

NUDGE-EHR Replication Trial at Mass General Brigham

NCT05538065
View directory record Official record
Conditions
Aging, Benzodiazepine Sedative Adverse Reaction, Anticholinergic Adverse Reaction, Adverse Drug Event
Interventions
Follow-up booster Alert, Pre-commitment, Enhanced Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Serious Adverse Events Following Angiography

NCT01467466
View directory record Official record
Conditions
Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions
IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

NCT05476679
View directory record Official record
Conditions
Submental Fat
Interventions
RZL-012, RZL-012+Lidacaine injection prior treatment, RZL-012+Medrol, RZL-012+Celecoxib+Zyrtec, RZL-012+facial and neck wrap
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Not applicable Interventional Results available

The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial

NCT02482025
View directory record Official record
Conditions
Drug-Related Side Effects and Adverse Reactions, Adverse Drug Events
Interventions
SMMRT
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Not applicable Interventional

Multi-Center Medication Reconciliation Quality Improvement Study

NCT01337063
View directory record Official record
Conditions
Adverse Drug Events, Medication Administered in Error
Interventions
Mentored medication reconciliation quality improvement
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
San Francisco, California • Johns Creek, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2015 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Not applicable Interventional Results available

Regional Data Exchange to Improve Care for Veterans After Non-VA Hospitalization

NCT02689076
View directory record Official record
Conditions
Patient Readmission, Adverse Drug Event, Cost
Interventions
HIE Notification, Care transitions intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 22, 2026, 11:33 PM EDT
Completed Phase 2Phase 3 Interventional

Improving Safety by Basic Computerizing Outpatient Prescribing

NCT01091038
View directory record Official record
Conditions
Adverse Drug Events
Interventions
Basic Clinical Decision Support, Routine Care
Other
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
228 participants
Timeline
2001 – 2007
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 22, 2026, 11:33 PM EDT